% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Bauer:873811,
      author       = {Bauer, Elena K. and Stoffels, Gabriele and Blau, Tobias and
                      Reifenberger, Guido and Felsberg, Jörg and Werner, Jan M.
                      and Lohmann, Philipp and Rosen, Jurij and Ceccon, Garry and
                      Tscherpel, Caroline and Rapp, Marion and Sabel, Michael and
                      Filss, Christian P. and Shah, Nadim J. and Neumaier, Bernd
                      and Fink, Gereon R. and Langen, Karl-Josef and Galldiks,
                      Norbert},
      title        = {{P}rediction of survival in patients with {IDH}-wildtype
                      astrocytic gliomas using dynamic
                      {O}-(2-[18{F}]-fluoroethyl)-l-tyrosine {PET}},
      journal      = {European journal of nuclear medicine and molecular imaging},
      volume       = {47},
      issn         = {1619-7089},
      address      = {Heidelberg [u.a.]},
      publisher    = {Springer-Verl.},
      reportid     = {FZJ-2020-01016},
      pages        = {1486–1495},
      year         = {2020},
      abstract     = {PurposeIntegrated histomolecular diagnostics of gliomas
                      according to the World Health Organization (WHO)
                      classification of 2016 has refined diagnostic accuracy and
                      prediction of prognosis. This study aimed at exploring the
                      prognostic value of dynamic
                      O-(2-[18F]-fluoroethyl)-l-tyrosine (FET) PET in newly
                      diagnosed, histomolecularly classified astrocytic gliomas of
                      WHO grades III or IV.MethodsBefore initiation of treatment,
                      dynamic FET PET imaging was performed in patients with newly
                      diagnosed glioblastoma (GBM) and anaplastic astrocytoma
                      (AA). Static FET PET parameters such as maximum and mean
                      tumour/brain ratios (TBRmax/mean), the metabolic tumour
                      volume (MTV) as well as the dynamic FET PET parameters
                      time-to-peak (TTP) and slope, were obtained. The predictive
                      ability of FET PET parameters was evaluated concerning the
                      progression-free and overall survival (PFS, OS). Using ROC
                      analyses, threshold values for FET PET parameters were
                      obtained. Subsequently, univariate Kaplan-Meier and
                      multivariate Cox regression survival analyses were performed
                      to assess the predictive power of these parameters for
                      survival.ResultsSixty patients (45 GBM and 15 AA patients)
                      of two university centres were retrospectively identified.
                      Patients with isocitrate dehydrogenase (IDH)-mutant or
                      O6-methylguanine-DNA-methyltransferase (MGMT)
                      promoter-methylated tumours had a significantly longer PFS
                      and OS (both P < 0.001). Furthermore, ROC analysis of
                      IDH-wildtype glioma patients (n = 45) revealed that a
                      TTP > 25 min (AUC, 0.90; sensitivity, $90\%;$
                      specificity, $87\%;$ P < 0.001) was highly prognostic
                      for longer PFS (13 vs. 7 months; P = 0.005) and OS (29
                      vs. 12 months; P < 0.001). In contrast, at a lower level
                      of significance, TBRmax, TBRmean, and MTV were only
                      prognostic for longer OS (P = 0.004, P = 0.038, and P
                      = 0.048, respectively). Besides complete resection and a
                      methylated MGMT promoter, TTP remained significant in
                      multivariate survival analysis (all P ≤ 0.02),
                      indicating an independent predictor for OS.ConclusionsOur
                      data suggest that dynamic FET PET allows the identification
                      of patients with longer OS among patients with newly
                      diagnosed IDH-wildtype GBM and AA.},
      cin          = {INM-3 / INM-4 / INM-5},
      ddc          = {610},
      cid          = {I:(DE-Juel1)INM-3-20090406 / I:(DE-Juel1)INM-4-20090406 /
                      I:(DE-Juel1)INM-5-20090406},
      pnm          = {572 - (Dys-)function and Plasticity (POF3-572)},
      pid          = {G:(DE-HGF)POF3-572},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:32034446},
      UT           = {WOS:000515952800001},
      doi          = {10.1007/s00259-020-04695-0},
      url          = {https://juser.fz-juelich.de/record/873811},
}